The authors describe an industrialized process for the manufacture of iPSC-derived human cardiomyocytes. This article is part of a special issue on Bioprocessing and Sterile Manufacturing.
Emile Nuwaysir
Advertisement
Emile Nuwaysir is COO at Cellular Dynamics International, 525 Science Drive, Madison, WI 53711.
Articles by Emile Nuwaysir
Advertisement
Latest Updated Articles
Industrialized Production of Human iPSC-Derived Cardiomyocytes for Use in Drug Discovery and Toxicity TestingPublished: March 1st 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The Regulatory Crucible: Risk, Resource Drain, and the Hidden Trade-Offs of the CNPV Pilot Program
2
Leveraging AI/ML to Reduce Risk in Drug Development: Part One
3
New Targets for Clinical Trials in the European Union
4
Molecular Dynamics and Quantum Calculations: AAPS Thermo Fisher Interview, Part Two
5
